Virpax Pharmaceuticals Inc
VRPX
Get informed when a big investor buys or sells
+ FollowMarket Cap$124
Close$
$0.36
355500% upside
Current Fair Value
355500% upsideUndervalued by 355500% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $124.00 |
|---|---|
| Enterprise Value | $-1,512,933.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-70.91 |
| Beta | 2.56 |
| Outstanding Shares | 4,254,403 |
Return
| Return on Equity | 1320.61% |
|---|---|
| Return on Assets | -775.72% |
| Return on Invested Capital | 1682.91% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.1 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Virpax Pharmaceuticals Inc
2 employeesVirpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery plat...